Autologous stem cell transplantation is currently considered the standard of care for multiple myeloma in young patients with adequate organ function, based on the results of trials conducted in the era prior to the advent of novel agents. While these trials demonstrated the superiority of high-dose
No takes yet. Share an insight, caveat, or question.
Mohty et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: